These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39006945)

  • 1. Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.
    Geoffroy K; Mullins-Dansereau V; Leclerc-Desaulniers K; Viens M; Bourgeois-Daigneault MC
    Mol Ther Oncol; 2024 Sep; 32(3):200826. PubMed ID: 39006945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
    Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
    Felt SA; Droby GN; Grdzelishvili VZ
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
    Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.
    Holbrook MC; Goad DW; Grdzelishvili VZ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
    Cataldi M; Shah NR; Felt SA; Grdzelishvili VZ
    Virology; 2015 Nov; 485():340-54. PubMed ID: 26331681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
    Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
    J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.
    Dold C; Rodriguez Urbiola C; Wollmann G; Egerer L; Muik A; Bellmann L; Fiegl H; Marth C; Kimpel J; von Laer D
    Mol Ther Oncolytics; 2016; 3():16021. PubMed ID: 27738655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
    Capo-chichi CD; Yeasky TM; Heiber JF; Wang Y; Barber GN; Xu XX
    Gynecol Oncol; 2010 Feb; 116(2):269-75. PubMed ID: 19932656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
    Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
    J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Goad DW; Bressy C; Holbrook MC; Grdzelishvili VZ
    Mol Ther Oncolytics; 2022 Mar; 24():59-76. PubMed ID: 34977342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.